Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder

Key Findings:  This mouse model of long-term use of CBD oil in Autism Spectrum Disorder (ASD) found a reduction of symptoms of anxiety and repetitive behaviors as well as a link to the mechanism of action within the CB1 receptors, glutamate, and alterations of RNA neurotransmission genes in the treatment group.

Type of Study:  Animal Study

Study Result:  Positive

Study Location(s):  Israel

Year of Pub:  2021

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Endocannabinoid (unspecified)

Phytocannabinoid Source:  Cannabis Flower derived

Chemotype:  Chemotype I, Chemotype III

Receptors Studied:  CB1

Ligands Studied:  GABA, Glutamate

Sub-Ratio: THC:CBD 1:25 THC:CBD 1:0

Dosage: CBD:THC (25 mg/kg:1 mg/kg) and THC (1 mg/kg)

Route of Administration:  Oral (Ingestion)

Link to study